Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
Academic Article
Overview
MeSH Major
Antineoplastic Agents
Benzamides
Gastrointestinal Stromal Tumors
Piperazines
Pyrimidines
abstract
The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence.
